Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Veterans Affairs and Emory University, demonstrating that parenteral GDNF (Glial Cell-Derived Neurotrophic Factor) directly reprograms liver fat metabolism at the genetic level in a preclinical model of metabolic-associated fatty liver disease (MAFLD).

 

The data highlights statistically significant improvements in key genes responsible for fat production and fat metabolism, positioning GDNF as a potentially differentiated therapeutic approach targeting the root cause of fatty liver disease and metabolic dysfunction.

  • Statistically significant reduction in Srebf1, a key gene driving fat production in the liver
  • Increased expression of Pparα, a central regulator of fat metabolism and fat burning
  • GDNF outperformed semaglutide in key gene expression markers tied to liver fat regulation
  • Demonstrated broad metabolic impact at the genetic level, not just weight reduction